Sandoz Scores European Approval for Biosimilar Rituximab
The European Commission approved Rixathon for use in all indications of its reference medicine, MabThera.
Sandoz, a division of Novartis, announced on June 19, 2017 that the European Commission (EC) has approved Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine, MabThera, the company said in a press release.
In a statement, Carol Lynch, global head of Biopharmaceuticals at Sandoz called the approval a “big win for patients in Europe with blood cancers or immunological diseases.” Rixathon is approved for non-Hodgkin's lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
The EC approval was based on a comprehensive development program generating analytical, preclinical, and clinical-including pharmacokinetic/pharmacodynamics-data, the company said. The program demonstrated Rixathon matches its reference medicine in terms of safety, efficacy, and quality.
Source: Novartis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
